UK-based private equity company Pamplona Capital Management has agreed to acquire Parexel International Corporation by acquiring the entire outstanding shares of the company in an all-cash transaction.

The purchase consideration for the acquisition has been fixed at $88.1 per share, valuing the transaction at $5bn inclusive of net debt.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The target company is a biopharmaceutical firm based in the US and will become a privately held company following the acquisition, which is expected to be completed by this year's fourth quarter.

"Spherix has reached an agreement to acquire a controlling stake in biopharmaceutical company, Hoth Therapeutics."

Spherix has reached an agreement to acquire a controlling stake in biopharmaceutical company, Hoth Therapeutics.

The acquirer company is a scientific research company also based in the US, and the acquisition is expected to increase Spherix’s shareholder value.

Quantum Hi-Tech China Biological has reached an agreement to acquire Shanghai ChemPartner, a contract research organisation.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Both companies involved in the acquisition are based in China. The acquisition is expected to be completed by the end of the year.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now